Assessing resectability for colorectal liver metastases: agreeing that we disagree

Expanding criteria for resectability of colorectal liver metastases.

Surgical resection is the treatment of choice in patients with colorectal liver metastases, with 5-year survival rates reported in the range of 40%-58%. Over the past 10 years, there has been an impetus to expand the criteria for defining resectability for patients with colorectal metastases. In the past, such features as the number of metastases (three to four), the size of the tumor lesion, a...

Euthanasia: agreeing to disagree?

In discussions about the legalisation of active, voluntary euthanasia it is sometimes claimed that what should happen in a liberal society is that the two sides in the debate "agree to disagree". This paper explores what is entailed by agreeing to disagree and shows that this is considerably more complicated than what is usually believed to be the case. Agreeing to disagree is philosophically p...

Agreeing to disagree: a survey

Agreeing to Disagree and Dilation

We consider Geanakoplos and Polemarchakis’s generalization of Aumman’s famous result on “agreeing to disagree”, in the context of imprecise probability. The main purpose is to reveal a connection between the possibility of agreeing to disagree and the interesting and anomalous phenomenon known as dilation. We show that for two agents who share the same set of priors and update by conditioning o...

Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.

BACKGROUND/AIM The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. METHODS Between May 2008...